Compare · DXCM vs EMBC
DXCM vs EMBC
Side-by-side comparison of DexCom Inc. (DXCM) and Embecta Corp. (EMBC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and EMBC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 118.1x EMBC ($285.0M).
- EMBC has been more active in the news (11 items in the past 4 weeks vs 9 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 9 for EMBC).
- Company
- DexCom Inc.
- Embecta Corp.
- Price
- -
- -
- Market cap
- $33.65B
- $285.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 9
- 11
- Recent ratings
- 25
- 9
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
Latest EMBC
- Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.
- President and CEO Kurdikar Devdatt bought $140,937 worth of shares (30,000 units at $4.70), increasing direct ownership by 4% to 804,919 units (SEC Form 4)
- SVP and CFO Elguicze Jacob bought $93,360 worth of shares (20,000 units at $4.67), increasing direct ownership by 7% to 309,139 units (SEC Form 4)
- Pres, Pharm Svc&Prod Mgmt, CLO Mann Jeffrey Z bought $99,800 worth of shares (20,000 units at $4.99), increasing direct ownership by 8% to 262,915 units (SEC Form 4)
- Director Hombach Robert J. bought $223,848 worth of shares (45,000 units at $4.97), increasing direct ownership by 70% to 109,587 units (SEC Form 4)
- Chief Human Resources Officer Casner Jean covered exercise/tax liability with 1,480 shares, decreasing direct ownership by 2% to 85,915 units (SEC Form 4) (for tax liability)
- SEC Form S-8 filed by Embecta Corp.
- SEC Form 10-Q filed by Embecta Corp.
- Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results